BIOMAT Database Logo BIOMAT Database Logo

Treatment of mucosal leishmaniasis with amphotericin B lipid complex (ABLC). 2018

Felipe Francisco Tuon, and Carolina Rocio Santos, and Juliette Cieslinski, and Regina Maia de Souza, and Rui Imamura, and Valdir Sabbaga Amato
Pontifícia Universidade Católica do Paraná, Escola de Medicina, Curitiba, Paraná, Brazil.

UI MeSH Term Description Entries
D007897 Leishmaniasis, Mucocutaneous A disease characterized by the chronic, progressive spread of lesions from New World cutaneous leishmaniasis caused by species of the L. braziliensis complex to the nasal, pharyngeal, and buccal mucosa some time after the appearance of the initial cutaneous lesion. Nasal obstruction and epistaxis are frequent presenting symptoms. Leishmaniases, Mucocutaneous,Mucocutaneous Leishmaniases,Mucocutaneous Leishmaniasis
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D000666 Amphotericin B Macrolide antifungal antibiotic produced by Streptomyces nodosus obtained from soil of the Orinoco river region of Venezuela. Amphocil,Amphotericin,Amphotericin B Cholesterol Dispersion,Amphotericin B Colloidal Dispersion,Fungizone
D000981 Antiprotozoal Agents Substances that are destructive to protozoans. Schizonticides,Agents, Antiprotozoal
D016896 Treatment Outcome Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series. Rehabilitation Outcome,Treatment Effectiveness,Clinical Effectiveness,Clinical Efficacy,Patient-Relevant Outcome,Treatment Efficacy,Effectiveness, Clinical,Effectiveness, Treatment,Efficacy, Clinical,Efficacy, Treatment,Outcome, Patient-Relevant,Outcome, Rehabilitation,Outcome, Treatment,Outcomes, Patient-Relevant,Patient Relevant Outcome,Patient-Relevant Outcomes

Related Publications

Felipe Francisco Tuon, and Carolina Rocio Santos, and Juliette Cieslinski, and Regina Maia de Souza, and Rui Imamura, and Valdir Sabbaga Amato
Successful treatment of Candida glabrata endophthalmitis with amphotericin B lipid complex (ABLC).
January 2000, The Journal of infection,
Felipe Francisco Tuon, and Carolina Rocio Santos, and Juliette Cieslinski, and Regina Maia de Souza, and Rui Imamura, and Valdir Sabbaga Amato
Comparative immunotoxicity evaluation of amphotericin B and ABELCET, an amphotericin B lipid complex (ABLC).
January 2006, International journal of toxicology,
Felipe Francisco Tuon, and Carolina Rocio Santos, and Juliette Cieslinski, and Regina Maia de Souza, and Rui Imamura, and Valdir Sabbaga Amato
Efficacies of amphotericin B lipid complex (ABLC) and conventional amphotericin B against murine coccidioidomycosis.
September 1992, The Journal of antimicrobial chemotherapy,
Felipe Francisco Tuon, and Carolina Rocio Santos, and Juliette Cieslinski, and Regina Maia de Souza, and Rui Imamura, and Valdir Sabbaga Amato
Treatment of mucosal leishmaniasis with a lipid formulation of amphotericin B.
January 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America,
Felipe Francisco Tuon, and Carolina Rocio Santos, and Juliette Cieslinski, and Regina Maia de Souza, and Rui Imamura, and Valdir Sabbaga Amato
Amphotericin B lipid complex (ABLC)-associated hypertension: case report and review.
December 1999, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America,
Felipe Francisco Tuon, and Carolina Rocio Santos, and Juliette Cieslinski, and Regina Maia de Souza, and Rui Imamura, and Valdir Sabbaga Amato
Amphotericin B lipid complex: in visceral leishmaniasis.
January 2004, Drugs,
Felipe Francisco Tuon, and Carolina Rocio Santos, and Juliette Cieslinski, and Regina Maia de Souza, and Rui Imamura, and Valdir Sabbaga Amato
Effect of amphotericin B lipid complex (ABLC) in very low birth weight infants.
February 2009, Pediatric nephrology (Berlin, Germany),
Felipe Francisco Tuon, and Carolina Rocio Santos, and Juliette Cieslinski, and Regina Maia de Souza, and Rui Imamura, and Valdir Sabbaga Amato
Outcomes associated with amphotericin B lipid complex (ABLC) prophylaxis in high-risk liver transplant patients.
February 2013, Medical mycology,
Felipe Francisco Tuon, and Carolina Rocio Santos, and Juliette Cieslinski, and Regina Maia de Souza, and Rui Imamura, and Valdir Sabbaga Amato
Intrapulmonary disposition of amphotericin B after aerosolized delivery of amphotericin B lipid complex (Abelcet; ABLC) in lung transplant recipients.
December 2010, Transplantation,
Felipe Francisco Tuon, and Carolina Rocio Santos, and Juliette Cieslinski, and Regina Maia de Souza, and Rui Imamura, and Valdir Sabbaga Amato
Safety evaluation of ABELCET, an amphotericin B lipid complex (ABLC): toxicity studies in rats.
January 2006, International journal of toxicology,
Copied contents to your clipboard!